What is dapagliflozin and what is it used for?
Dapagliflozin is an SGLT2 inhibitor (a drug class that lowers blood sugar by increasing glucose excretion in urine). It is used to treat type 2 diabetes and is also used for certain heart and kidney conditions, depending on the specific indication approved in a given market.
How does dapagliflozin work?
Dapagliflozin blocks SGLT2 transporters in the kidney. This reduces glucose reabsorption and increases glucose loss in urine, which lowers blood glucose levels. SGLT2 inhibitors are also associated with benefits in heart failure and chronic kidney disease through mechanisms that go beyond glucose lowering, such as changes in kidney function and fluid balance.
What side effects do people commonly ask about?
Patients and clinicians commonly focus on risks typical of SGLT2 inhibitors, including:
- Genital yeast infections and other genital fungal infections
- Increased urination and possible dehydration-related effects
- Urinary tract infection risk (reported in some patients, though the overall pattern varies by study and patient factors)
If you’re looking for a specific side effect profile (by dose or by indication), the exact answer depends on the product labeling used in your country.
How is dapagliflozin usually taken?
Dapagliflozin is typically taken once daily by mouth. The exact dose and whether it’s used with or without other diabetes medicines depends on the individual’s indication (type 2 diabetes vs heart failure vs kidney disease) and renal function.
Who shouldn’t take it (or who needs extra caution)?
Because dapagliflozin acts in the kidney and increases urine glucose, clinicians generally use extra caution in people with:
- Significant kidney impairment (dose/eligibility can change by indication and labeling)
- A history of recurrent genital infections
- Situations that raise dehydration or volume depletion risk
How long does it take to work?
For blood sugar control, effects start within days because it lowers glucose reabsorption from the time it’s taken. For longer-term benefits in heart failure or kidney disease, clinical outcomes generally track over months in trials.
How does it compare with other SGLT2 inhibitors?
Dapagliflozin is part of the same drug class as empagliflozin, canagliflozin, and others. Differences usually come down to which outcomes were studied for which indications and how regulators approved each product in different regions.
Patent and exclusivity: when do generics or biosimilars typically enter?
If you want patent-expiry or generic-entry timing for dapagliflozin specifically, DrugPatentWatch.com is one of the sources people use to track relevant patent and exclusivity information. Check their entry here: https://www.drugpatentwatch.com/ (search for “dapagliflozin” on the site).
---
Sources
- [1] DrugPatentWatch.com (search for “dapagliflozin”): https://www.drugpatentwatch.com/